title: A prospective open-label trial of paliperidone monotherapy for the treatment of bipolar spectrum disorders in children and adolescents.
abstract: BACKGROUND
  Treatment studies for the management of pediatric bipolar disorder are limited.
  
  
  OBJECTIVE
  This study evaluates the safety and efficacy of paliperidone monotherapy as an acute treatment of mania and related symptoms in youth with bipolar spectrum disorders.
  
  
  METHODS
  An 8-week, prospective, open-label paliperidone monotherapy trial to assess effectiveness and tolerability in treating pediatric bipolar spectrum and related disorders (depression, psychosis, attention-deficit/hyperactivity disorder [ADHD]). Assessments included the Young Mania Rating Scale (YMRS), Clinical Global Impression scale (CGI), Children's Depression Rating Scale-Revised (CDRS-R), and Brief Psychiatric Rating Scale (BPRS). Adverse events were assessed through spontaneous self-reports, vital signs, weight monitoring, and laboratory analysis.
  
  
  RESULTS
  Fifteen youth with bipolar spectrum disorders (YMRS at entry: 32.8 ± 6.1) were enrolled in the study and 11 (73 %) completed the 8-week trial. The total daily dose of paliperidone at study endpoint was 3 mg in 12 subjects and 6 mg in three subjects. Treatment with paliperidone was associated with statistically significant levels of improvement in mean YMRS scores (-18.7 ± 13.9, p < 0.001) at endpoint. Paliperidone treatment also resulted in significant improvement in the severity of ADHD and psychotic symptoms. Although treatment with paliperidone was generally well tolerated and was not associated with clinically significant change in cardiovascular or metabolic parameters, increases in body weight (4.1 ± 5.5 lb) were substantial.
  
  
  CONCLUSIONS
  Open-label paliperidone treatment appears to be beneficial in the treatment of bipolar spectrum disorders and associated conditions in youth. Future placebo-controlled studies are warranted to confirm these findings.
authors: Clinical and Research Program in Pediatric Psychopharmacology and Adult ADHD, Massachusetts General Hospital, and Department of Psychiatry, Harvard Medical School, 55 Fruit Street, YAW 6900, Boston, MA 02114, USA.
authors: Gagan
authors: G
authors: Joshi
authors: Carter
authors: C
authors: Petty
authors: Janet
authors: J
authors: Wozniak
authors: Stephen V
authors: SV
authors: Faraone
authors: Andrea E
authors: AE
authors: Spencer
authors: K Yvonne
authors: KY
authors: Woodworth
authors: Rachel
authors: R
authors: Shelley-Abrahamson
authors: Hannah
authors: H
authors: McKillop
authors: Stephannie L
authors: SL
authors: Furtak
authors: Joseph
authors: J
authors: Biederman
mesh_terms: D000293:Adolescent; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000188:drug therapy* / Q000523:psychology; D002648:Child; D005260:Female; D006801:Humans; D007555:Isoxazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D000068882:Paliperidone Palmitate; D010865:Pilot Projects; D011446:Prospective Studies; D011569:Psychiatric Status Rating Scales; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents; D007555:Isoxazoles; D011743:Pyrimidines; D000068882:Paliperidone Palmitate
references: J Child Adolesc Psychopharmacol. 2009 Oct;19(5):539-45
references: 19877978
references: J Clin Child Adolesc Psychol. 2002 Dec;31(4):567-72
references: 12402575
references: J Affect Disord. 2002 Aug;70(3):323-7
references: 12128245
references: J Clin Psychiatry. 1986 Nov;47(11):566-7
references: 3771504
references: Neuropsychiatr Dis Treat. 2008 Feb;4(1):203-7
references: 18728799
references: J Child Adolesc Psychopharmacol. 2005 Apr;15(2):311-7
references: 15910215
references: Arch Gen Psychiatry. 2012 May;69(5):515-28
references: 22213771
references: Psychol Assess. 2001 Sep;13(3):384-95
references: 11556275
references: J Am Acad Child Adolesc Psychiatry. 1994 May;33(4):461-8
references: 8005898
references: J Am Acad Child Adolesc Psychiatry. 1996 Aug;35(8):997-1008
references: 8755796
references: J Child Adolesc Psychopharmacol. 2003 Winter;13(4):449-51
references: 14977457
references: J Clin Psychiatry. 2012 Mar;73(3):358-65
references: 22154898
references: J Am Acad Child Adolesc Psychiatry. 1995 Apr;34(4):454-63
references: 7751259
references: J Clin Psychiatry. 2011 Sep;72(9):1250-6
references: 21672501
references: J Am Acad Child Adolesc Psychiatry. 2012 Sep;51(9):867-78
references: 22917200
references: J Affect Disord. 2012 Feb;136(3):1143-53
references: 22035648
references: Br J Psychiatry. 1978 Nov;133:429-35
references: 728692
references: Bipolar Disord. 2007 Dec;9(8):888-94
references: 18076539
references: Arch Gen Psychiatry. 1976 Jun;33(6):766-71
references: 938196
references: Pediatrics. 1979 Oct;64(4):442-50
references: 492809
references: Ann Clin Psychiatry. 1995 Sep;7(3):127-32
references: 8646272
references: Biol Psychiatry. 2000 Sep 15;48(6):458-66
references: 11018219
references: J Am Acad Child Adolesc Psychiatry. 1997 Nov;36(11):1552-9; discussion 1559-60
references: 9394940
references: J Clin Psychopharmacol. 2007 Feb;27(1):6-14
references: 17224706
references: Biol Psychiatry. 1986 Sep;21(11):1107-9
references: 3741930
references: CNS Spectr. 2007 Sep;12(9):683-9
references: 17805214
references: J Am Acad Child Adolesc Psychiatry. 2011 Aug;50(8):749-62.e39
references: 21784295
references: J Am Acad Child Adolesc Psychiatry. 1992 Mar;31(2):252-7
references: 1564026
references: Schizophr Res. 2007 Feb;90(1-3):147-61
references: 17092691